@article{JGO14866,
author = {Sachin G. Pai and Benedito A. Carneiro and Young Kwang Chae and Ricardo L. Costa and Aparna Kalyan and Hiral A. Shah and Irene Helenowski and Alfred W. Rademaker and Devalingam Mahalingam and Francis J. Giles},
title = {Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: The Cancer Genome Atlas (TCGA) showed that 16% of colorectal cancers (CRC) display DNA repair mechanisms and high tumor mutational burden (TMB). Although, there is accumulating evidence of greater benefit of immunotherapy in tumors with high-TMB, its impact on response to chemotherapy is unknown.
Methods: In this retrospective cohort study, we investigated the impact of TMB on progression-free survival (PFS) of CRC patients treated at tertiary care oncology clinics who had their tumors profiled by next-generation sequencing (NGS). Low TMB (TMB-L) and intermediate/high TMB (TMB-I/H) were defined as ≤5 mutations per base (MB) or ≥6 MB, respectively.
Results: Seventy-four CRC patients (61 colon and 13 rectal cancers) were identified from the database. In the TMB-L cohort, irinotecan-based chemotherapy treated patients had improved PFS compared to oxaliplatin-based chemotherapy treated patients (11.9 vs. 6.5 months, P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/14866}
}